

DAFTAR PUSTAKA

- Abdelraouf, E. M., Hussein, R. R. S., Shaaban, A. H., El-Sherief, H. A. M., Embaby, A. S., & Abd El-Aleem, S. A. (2022). Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. *Life Sciences*, 308, 120967.
- Abdollahi, M., Hajizadeh, E., Haghghat, S., & Baghestani, A. R. (2018). *Prognostic Cut Point for Breast Cancer Age of Diagnosis*.
- Adiputra, P. A. T., & Sudarsa, I. W. (n.d.). *Skoring Prognostik Survival Pasien Triple Negative Breast Cancer Berbasis Immunoscore*.
- Al-Zawi, A. S. A., Elamass, M., Kapturek, A., & Idaewor, P. (2021). Ki-67 proliferative index correlation to the immunohistochemistry profile in early female breast cancer: a review of 515 cases. *Medical Research Journal*, 6(2), 108–113.
- Andrés-Sánchez, N., Fisher, D., & Krasinska, L. (2022). Physiological functions and roles in cancer of the proliferation marker Ki-67. *Journal of Cell Science*, 135(11), jcs258932.
- Ardhiansyah, A. O. (2021). *Dasar-dasar Onkologi dan Hallmark of Cancer (Edisi 2): dari teori preklinik hingga aplikasi klinik* (Vol. 1). Airlangga University Press.
- Arnold, M., Morgan, E., Rungay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., & Siesling, S. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. *The Breast*, 66, 15–23.
- Arzanova, E., & Mayrovitz, H. N. (2022). The Epidemiology of Breast Cancer. *Exon Publications*, 1–19.
- Ayoub NM, Al-Shami KM, Alqudah MA, Mhaidat NM. 2017. Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. *Onco Targets Ther* 5;10:4869-4883.
- Badowska-Kozakiewicz, A., Budzik, M., Liszcz, A., Sobieraj, M., Czerw, A., Sobol, M., Patera, J., & Deptała, A. (2018). Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer. *Archives of Medical Science*, 15(6), 1433–1442.
- Bistoni, G., & Farhadi, J. (2015). Anatomy and physiology of the breast. *Plastic and Reconstructive Surgery: Approaches and Techniques*, 477–485.
- Biswas, R. S. R. (2020). Molecular subtypes of breast cancer patients according to St Gallen classification. *Chattagram Maa-O-Shishu Hospital Medical College Journal*, 19(1), 55–58.

- Bland, Kirby I., Helena R. Chang, and Edward M. Copeland III. "Modified radical mastectomy and simple mastectomy." *The breast*. Elsevier, 2018. 443-461.
- Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., Van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., & Blomqvist, C. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, 7(5), e1000279.
- Braicu, C., Chiorean, R., Irimie, A., Chira, S., Tomuleasa, C., Neagoe, E., Paradiso, A., Achimas-Cadariu, P., Lazar, V., & Berindan-Neagoe, I. (2016). Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. *Expert Reviews in Molecular Medicine*, 18, e18.
- Chaudhary, L. N. (2020). Early stage triple negative breast cancer: management and future directions. *Seminars in Oncology*, 47(4), 201–208.
- Chiorean, R., Braicu, C., & Berindan-Neagoe, I. (2013). Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? *The Breast*, 22(6), 1026–1033.
- Choi, S. B., Park, J. M., Ahn, J. H., Go, J., Kim, J., Park, H. S., Kim, S. Il, Park, B.-W., & Park, S. (2022). Ki-67 and breast cancer prognosis: does it matter if Ki- 67 level is examined using preoperative biopsy or postoperative specimen? *Breast Cancer Research and Treatment*, 192(2), 343–352.
- Collignon, J., Lousberg, L., Schroeder, H., & Jerusalem, G. (2016). Triple-negative breast cancer: treatment challenges and solutions. *Breast Cancer: Targets and Therapy*, 93–107.
- Costa, R. E. A. R. da, Oliveira, F. T. R. de, Araújo, A. L. N., & Vieira, S. C. (2021). Prognostic factors in triple-negative breast cancer: a retrospective cohort. *Revista Da Associação Médica Brasileira*, 67, 950–957.
- Cota, B.D.C.V., Lima, K.S., Murad, A.M.. 2017. Expression of the c-MET, HGF and VEGF biomarkers in intestinal and diffuse gastric cancer in the Brazilian population: a pilot study for the standardization of the quantitative PCR technique. 37, 18
- da Silva, J. L., Nunes, N. C. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020). Triple negative breast cancer: A thorough review of biomarkers. *Critical Reviews in Oncology/Hematology*, 145, 102855.
- Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. (2021). Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. *Cancers (Basel)*. 3;13(17):4455.

- Demkova, Lucia & Kucerova, Lucia. (2018). Role of the HGF/c-MET tyrosine kinase inhibitors in metastatic melanoma. *Molecular Cancer*, 17. 10.1186/s12943-018-0795-z.
- Denkert, C., Loibl, S., Müller, B. M., Eidtmann, H., Schmitt, W. D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., & Huober, J. (2013). Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvan GeparTrio trial. *Annals of Oncology*, 24(11), 2786–2793.
- do Nascimento, R. G., & Otoni, K. M. (2020). Histological and molecular classification of breast cancer: what do we know? *Mastology*, 30, 1–8.
- Elleithy, Nehal Ali Yehia et al. 2020, “Immunohistochemical Expression of “c-MET” in Breast Carcinomas.” *Open Access Macedonian Journal of Medical Sciences* 8: 824-832.
- Ensenyat-Mendez, M., Llinàs-Arias, P., Orozco, J. I. J., Íñiguez-Muñoz, S., Salomon, M. P., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021). Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer. *Frontiers in Oncology*, 11, 681476.
- Fan, Y., & He, S. (2022). The characteristics of tumor microenvironment in triple negative breast cancer. *Cancer Management and Research*, 1–17.
- Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674.
- Gaule PB, Crown J, O'Donovan N, Duffy MJ. 2014. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? 18(9):999-1009.
- Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018). of the AJCC cancer staging manual: breast cancer. *Annals of Surgical Oncology*, 25, 1783–1785.
- Gnant, M., Thomssen, C., & Harbeck, N. (2015). St. Gallen/Vienna 2015: a brief summary of the consensus discussion. *Breast Care*, 10(2), 124–130.
- Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., & Bergh, J. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, 24(9), 2206–2223.
- Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. 2009. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. *Proc Natl Acad Sci U S A*. Aug 4;106(31):12909-14.
- Griffiths C, Olin J, 2012, Triple negative breast cancer: a brief review of its characteristics and

- Hadiyanto, A. V. S., Miranti, I. P., Prajoko, Y. W., & Istiadi, H. (2022). Histological and Clinical Stage Profiles of Young-aged Breast Carcinoma. *Diponegoro International Medical Journal*, 3(1), 1–6.
- Ho-Yen, C.M., Jones, J.L. & Kermorgant, S. 2015, The clinical and functional significance of c-Met in breast cancer: a review. *Breast Cancer Res* 17, 52
- Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S, Jones JL. 2014. C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? *Cancer*. 120(2), 163-71
- Hamm, C., Kulkarni, S., Gupta, R., Kay, A., Mathews, J., Hirmiz, K., Woldie, I., Ghafoor, A., Elfiki, T., & Kanjeekal, S. (2016). Early Stage triple negative breast cancer has significantly better outcomes than more advanced disease: a single centre retrospective review. *Journal of Cancer Therapy*, 7(10), 665.
- Han K, Chanu P, Jonsson F, Winter H, Bruno R, Jin J, Stroh M. (2017). Exposure-response and tumor growth inhibition analyses of the monovalent anti-c-MET antibody onartuzumab (MetMab) in the second- and third-line non-small cell lung cancer, 19, 527-533.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–674.
- Hashmi, A. A., Hashmi, K. A., Irfan, M., Khan, S. M., Edhi, M. M., Ali, J. P., Hashmi, S. K., Asif, H., Faridi, N., & Khan, A. (2019). Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. *BMC Research Notes*, 12(1), 1–5.
- Hochgraefe F, Zhang L, O'Toole SA, et al. 2010. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. *Cancer Res*;70(22):9391-401
- Hoeflerlin, L. A., Chalfant, C. E., & Park, M. A. (2013). Challenges in the treatment of triple negative and HER2-overexpressing breast cancer. *Journal of Surgery and Science*, 1(1), 3.
- Hortobagyi, G. N., Edge, S. B., & Giuliano, A. (2018). New and important changes in the TNM staging system for breast cancer. *American Society of Clinical Oncology Educational Book*, 38, 457–467.
- Ho-Yen, C.M., Green, A.R., Rakha, E.A., Brentnall, A.R., Ellis, I.O., Kermorgant, S. and Jones, J.L. (2014), C-Met in invasive breast cancer. *Cancer*, 120: 163-171.
- Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, Perrone A, Zito Marino F, Panarese I, Tathode MS, Caraglia M, Gatta G, Ruggiero R, Parisi S, De Vita F, Ciardiello

- F, Docimo L, Orditura M. 2022. Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis. *J Clin Med*.11(23),6987.
- Jia L, Yang X, Tian W, Guo S, Huang W, Zhao W. 2018. Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome. 24, 8239–8249
- Jung HY, Joo HJ, Park JK, Kim YH. 2012. The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer. *Cancer Res Treat*. 44(4), 251-61.
- Keam B, Im SA, Lee KH. (2011), Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Research*. 13:R22.
- Lengyel, Ernst. 2005. "C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu." *International journal of cancer* 113.4 : 678-682.
- Li E, Hu Z, Sun Y, Zhou Q, Yang B, Zhang Z. 2016. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
- Liedtke, C., Hess, K. R., Karn, T., Rody, A., Kiesel, L., Hortobagyi, G. N., Pusztai, L., & Gonzalez-Angulo, A. M. (2013). The prognostic impact of age in patients with triple-negative breast cancer. *Breast Cancer Research and Treatment*, 138, 591–599.
- Lin, S., Mo, H., Li, Y. *et al.* 2021. Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population. *BMC Cancer* **21**, 1330 (2021).
- Lindemann K, Resau J, N€ahrig J, et al. 2007, Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent nor-mal breast tissue.*Histopathology*;51:54-62
- Lugano, R., Ramachandran, M., & Dimberg, A. (2020). Tumor angiogenesis: causes, consequences, challenges and opportunities. *Cellular and Molecular Life Sciences*, 77, 1745–1770.
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*, 13(17), 4287.
- Medová M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y. 2010. MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-

- Mehta, Anurag, et al. "Diagnostic ability of real-time quantitative polymerase chain reaction versus immunohistochemistry for Ki-67 assessment in breast cancer: An Indian perspective." *The Indian Journal of Medical Research* 150.3 (2019): 254.
- M. J. Engstrøm, S. Opdahl, A. I. Hagen, P. R. Romundstad, L. A. Akslen, O. A. Haugen, L. J. Vatten & A. M. Bofin. 2013. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients Volume 140, pages 463–473
- Motomura H., Nozaki Y., Onaga C, Ozaki A., Tamori S, Taka-Aki Shiina, Shotaro Kanai, Ohira C, Hara Y, Harada Y, Takasawa R, Hanawa T, Tanuma S., Yasunari Mano Y., Sato T, Sato K., Akimoto K, 2017 High Expression of *c-Met*, *PKCλ* and *ALDH1A3* Predicts a Poor Prognosis in Late-stage Breast Cancer. 40, 35-52
- Munzone, Elisabetta, et al. "Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer." *Breast cancer research and treatment* 134 (2012): 277-282.
- Nurmayeni, N., & Windarti, I. (2022). Gambaran Subtipe Molekuler Kanker Payudara di Indonesia. *Jurnal Agromedicine*, 9(2), 146–149.
- Organization, W. H., Cancer, I. A. for R. on, & Organization, W. H. (2020). *Global cancer observatory*.
- Ostad, S. N., & Parsa, M. (2011). Breast cancer from molecular point of view: Pathogenesis and biomarkers. *Breast Cancer—Focusing Tumor Microenvironment, Stem Cells and Metastasis*.
- Park, S., Park, S., Kim, J., Ahn, S., Park, K. H., & Lee, H. (2018). Assessment of Ki-67 for predicting effective prognosis in breast cancer subtypes. *Biomedical Science Letters*, 24(1), 9–14.
- Pascual, M. C., Montaña, J. J., Franch, P., Sánchez-Contador, C., & Ramos, M. (2022). Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain. *Journal of Clinical Medicine*, 11(19), 5708.
- Phillips, L., Gill, A. J., & Baxter, R. C. (2019). Novel prognostic markers in triple-negative breast cancer discovered by MALDI-mass spectrometry imaging. *Frontiers in Oncology*, 9, 379.
- Piedra-Delgado, Luis, et al. "Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience." *Plos one* 19.2 (2024): e0293833
- Pogoda, K., Niwińska, A., Murawska, M., & Pieńkowski, T. (2013). Analysis of pattern, time

and risk factors influencing recurrence in triple-negative breast cancer patients. *Medical Oncology*, 30, 1–8.

- Purwanto, I., Dwiprahasto, I., Aryandono, T., & Mubarika, S. (2020). Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement. *J Med Sci*, 52(1), 81–101.
- Raghav, K.P., Wang, W., Liu, S., Chavez-MacGregor, M., Meng, X., Hortobagyi, G.N., Mills, G.B., Meric-Bernstam, F., Blumenschein Jr, G.R. and Gonzalez-Angulo, A.M., 2012. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. *Clinical Cancer Research*, 18(8), pp.2269-2277.
- Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, Jha SK, Jha NK, Slama P, Roychoudhury S, Kumar D. 2022. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. *Mol Cancer*. 26;21(1):31.
- Rao, C., Shetty, J., & Prasad, K. H. L. (2013). Immunohistochemical profile and morphology in triple-Negative breast cancers. *Journal of Clinical and Diagnostic Research: JCDR*, 7(7), 1361.
- Reddy, S. M., Sinha, A. K., Hsu, L., Barcenas, C. H., & Valero, V. (2016). *Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus < 1%)*. American Society of Clinical Oncology.
- Simon, Sérgio Daniel, Pedro HZ de Moraes, and Vladimir Galvão de Aguiar. "Adjuvan Chemotherapy of Breast Cancer." *Breast Diseases: An Evidence-Based Pocket Guide* (2019): 489-495.
- Singh, D., Roy, N., & Das, S. M. (2020). Epidemiology, pattern of recurrence and survival in triple-negative breast cancer. *Asian Pacific Journal of Cancer Care*, 5(2), 87–94.
- Sobri, F. B., Azhar, Y., Wibisana, I. G. N., & Rachman, A. (2017). Manajemen terkini kanker payudara. *Media Aesculapius, Jakarta*.
- Solid, T. W. P. P. K. (2010). *Panduan Penatalaksanaan Kanker Payudara*. PERABOI.
- Song, Z., Chang, Y., Jia, H., Xu, B., Yang, L., Xu, Y., Zhang, J., Wang, M., & Yang, L. (2022). *Metadherin inhibits triple-negative breast cancer chemosensitivity to paclitaxel via activation of the AKT/GSK-3β signaling pathway*.
- Sood, N., & Nigam, J. S. (2014). Correlation of CK5 and EGFR with clinicopathological profile of triple-negative breast cancer. *Pathology Research International*, 2014.
- Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in

- Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021). Triple-negative breast cancer: Promising prognostic biomarkers currently in development. *Expert Review of Anticancer Therapy*, 21(2), 135–148.
- Sun B, Liu R, Xiao Z-D, Zhu X. 2012 c-MET Protects Breast Cancer Cells from Apoptosis Induced by Sodium Butyrate. *PLoS ONE* 7(1): e30143.
- Suyatno, R. K. A., Andinata, B., Iskandar, R. R., & Wibisana, I. G. (2020). Panduan penatalaksanaan kanker. *PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia)*, 115.
- Swede, H., Sarwar, A., Magge, A., Braithwaite, D., Cook, L. S., Gregorio, D. I., Jones, B. A., R Hoag, J., Gonsalves, L., & L Salner, A. (2016). Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. *Cancer Causes & Control*, 27, 627–636.
- Tan AS, Yeong JP, Lai CP. (2019). The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. *Virchows Arch* ;475:709-725
- Tan, H., & Fu, D. (2023). Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study. *Journal of Cancer Research and Therapeutics*.
- Turkman, Y. E. (2015). Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. *Number 1/February 2015*, 19(1), 62–67.
- Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. (2015) Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. *PLoS ONE* 10(7): e0119565. <https://doi.org/10.1371/journal.pone.0119565>
- Urruticochea, A., Smith, I. E., & Dowsett, M. (2005). Proliferation marker Ki-67 in early breast cancer. *Journal of Clinical Oncology*, 23(28), 7212–7220
- Valachis, A., Nyström, P., Fredriksson, I., Wennstig, A.-K., & Ahlgren, J. (2021). Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer. *Journal of Geriatric Oncology*, 12(2), 212–218.
- Wang W., Wu J, Zhang P, (2016) . Prognostic and predictive value of Ki-67 in triple-negative breast cancer. *Oncotarget*. 7:31079-31087
- Wang, X., Jiang, Y.-Z., Li, J.-J., Song, C.-G., & Shao, Z.-M. (2016). Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. *Oncotarget*, 7(29), 46636.
- Widodo, I., Dwianingsih, E. K., Anwar, S. L., Triningsih, F. E., Utoro, T., & Aryandono, T.

(2017). Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. *Asian Pacific Journal of Cancer Prevention: APJCP*, 18(5), 1251.

Wood GE, Hockings H, Hilton DM, Kermorgant S. 2021 The role of MET in chemotherapy resistance. *Oncogene*. 2021 40(11), 1927-1941.

Wu Q, Ma G, Deng Y. (2019), Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. *Front Oncol*. 9:1068

Yan S, Jiao X, Zou H, Li K. (2015). Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. 10, 62.

Yavuz, B. B., Aktan, M., & Kanyilmaz, G. (2022). Prognostic Factors in Patients with Triple Negative Breast Cancer Undergoing Adjuvan Radiotherapy: A 10-Year Single Center Experience: Triple negative breast cancer. *Archives of Breast Cancer*, 377–385.

Yin, J., Zhu, C., Wang, G., & Gu, J. (2022). Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses. *International Journal of General Medicine*, 5901–5914.

Zagouri, F., et al. "High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer." *British journal of cancer* 108.5 (2013): 1100-1105.

Zerdan B, Ghorayeb M, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z. Triple Negative Breast Cancer, 2022, Updates on Classification and Treatment in 2021. 14(5), 1253.

Zhao X, Qu J, Hui Y, Zhang H, Sun Y, Liu X, Zhao X, Zhao Z, Yang Q, Wang F, Zhang S. 2017. Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. 8(34), 56758-56767.

Saavedra C, Gion M, Cortés J, Llombart-Cussac A. 2023. Top advances of the year: Breast cancer. *Cancer*. 129(12), 1791-1794.

Tan, H., & Fu, D. (2023). Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study. *Journal of Cancer Research and Therapeutics*

Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, Dimopoulos MA, Filipits M. 2013. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. *Br J Cancer*. 2013 Mar 19;108(5):1100-5. doi: 10.1038/bjc.2013.31.



UNIVERSITAS
GADJAH MADA

Hubungan antara Ekspresi c-Met Tyrosine Kinase dan ki-67 pada Triple Negative Breast Cancer Operable dengan Disease Free Survival.

William Sugandhi, dr. Kunta Setiaji, Sp.B. Subsp.Onk (K); Prof. Dr. dr. Teguh Aryandono, Sp.B Subsp.Onk (K); dr. Pa

Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Zhang, Y., Xia, M., Jin, K. 2018. Function of the c-Met receptor tyrosine kinase in

carcinogenesis and associated therapeutic opportunities. *Mol Cancer* 17, 45